Molecular Partners vs TScan Therapeutics
MOLN and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MOLN and TCRX compare
TScan Therapeutics grew revenue faster over the last twelve months (−38.4% versus −100% for Molecular Partners).
TScan Therapeutics scores higher on the StockData Score (4 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MOLN | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $12.6M |
| Share price | $3.09 | $0.186 |
| Change, 1 year | −27.3% | −83.0% |
| Change, 5 years | −70.4% | −97.9% |
| Beta (5Y) | 0.90 | 0.94 |
| Employees | 34 | 142 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.4× |
| P/B | – | 0.3× |
| FCF yield | – | −888% |
| Fair value | – | $0.857 |
| Margin of safety | – | 78.3% |
| Growth | ||
| Revenue growth (TTM) | −100% | −38.4% (better) |
| Revenue growth, 5Y average | – | 56.9% |
| Profitability | ||
| Operating margin | – | −2247% |
| Net margin | – | −2219% |
| FCF margin | – | −2153% |
| Return on equity | – | −126% |
| Financial health | ||
| Debt / equity | – | 0.87 |
| Interest coverage | −11.5× (better) | −40.7× |
| Current ratio | 7.27 (better) | 2.03 |
| Altman Z-score | – | −8.19 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 8.9% | 53.5% |
| Held by insiders | 0.00% | 32.8% |
| Insider net buying, 12 months | – | $146K |
| Short interest, % of float | – | 4.4% |
Go deeper
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.